Sijibio Obtains Approval for Electric Medical Suction Device 'Curasys2'

Sijibio 'Curasis2'

[Asia Economy Reporter Lee Chun-hee] Sigibiotech announced on the 21st that it has obtained domestic approval for the second-generation product of the electric medical suction device 'Curasys', named 'Curasys2'.

Curasys is the only electric medical suction device manufactured domestically in Korea. It is used together with Curasac, a foam-type negative pressure wound dressing. It was developed based on the principle of negative pressure wound therapy (NPWT), which continuously suctions exudate generated from wounds by applying negative pressure to the wound area. In addition to protecting the wound and preventing contamination, it promotes the formation of capillaries and granulation tissue, enabling rapid healing of hard-to-heal wounds.

Curasys2 has improved durability by applying high-strength plastic exterior compared to the existing Curasys. It also features a low-center design and lightweight construction, equipped with holder and strap fixation, and an adapter device, allowing it to be moved and used without special cables, thereby enhancing safety during use. Convenience was also improved by adding touch button functionality and alarm mute function.

In particular, Curasys2 is compatible with the existing Curasac and Curasac Silver products used with the previous Curasys model, allowing existing users to use it without any issues.

According to the treatment material claim information statistics from the Health Insurance Review and Assessment Service, the market size for negative pressure wound therapy devices was 4.5 billion KRW as of last year, with Curasys and Curasac holding about 67% market share, maintaining the industry's number one position.

Sigibiotech plans to maintain its number one domestic market share with the launch of Curasys2, while further expanding its market share in major Asian countries such as China, Vietnam, and Thailand where it is currently exporting. Additionally, it aims to enter advanced countries such as the United States and Japan, where the market size reaches 2 trillion KRW annually, through a reverse innovation strategy.

Yoo Hyun-seung, CEO of Sigibiotech, said, "We have launched the Curasys product that further enhances patient convenience and device durability," adding, "We will continue to upgrade to better quality products by reflecting vivid feedback from clinical sites to increase satisfaction among medical staff and patients."